Nuwellis (NUWE) Stock: Buy, Sell, or Hold?
NUWE - Nuwellis, Inc. Common Stock
$0.69
-0.06 (-7.37%)
▼
5d:
-10.57%
30d:
-6.12%
90d:
-78.91%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When NUWE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NUWE is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NUWE is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NUWE is currently trading at $0.69, which is considered oversold relative to its 30-day fair value range of $0.73 to $0.92.
Technical Outlook: Technically, NUWE is showing sideways momentum. The price is currently testing key support at $0.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+1485.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUWE is showing sideways momentum. The price is currently testing key support at $0.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+1485.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.73 -
$0.92
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.4%)
- BULLISH: Trading 1485.5% below Wall St target ($11.00)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.73 -
$0.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.69
Resistance Level
$0.89
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.10
Wall Street Target
$11.00
(+1485.5%)
Revenue Growth (YoY)
14.1%
Earnings Growth (YoY)
-99.2%
Profit Margin
-125.6%
Share & Embed Analysis
Last updated: October 03, 2026 8:32 PM ET
Data refreshes hourly during market hours. Next update: 9:32 PM
Data refreshes hourly during market hours. Next update: 9:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUWE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 69 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 47 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 58 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 38 SELL |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$83 | 60 BUY |
